Anne-Joy M de Graan1, Alex Sparreboom1,2, Peter de Bruijn1, Evert de Jonge3, Bronno van der Holt4, Erik A C Wiemer1, Jaap Verweij1, Ron H J Mathijssen1, Ron H N van Schaik3. 1. Department of Medical Oncology, Erasmus MC Cancer Institute, 's-Gravendijkwal 230, 3015CE, Rotterdam. 2. Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, 262 Danny Thomas Place, 38105-3678, Memphis, TN, USA. 3. Department of Clinical Chemistry, Erasmus University Medical Center, 's-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands. 4. Department of Trials and Statistics, Erasmus University Medical Center, 's-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands.
Abstract
AIM: Taxanes are anti-cancer agents used to treat several types of solid tumours. They are metabolized by cytochrome P450 (CYP) 3A, displaying a large pharmacokinetic (PK) variability. In this study, we evaluated the endogenous CYP3A4 marker 4β-hydroxycholesterol (4β-OHC) as a potential individual taxane PK predictor. METHODS: Serum 4β-OHC and cholesterol concentrations were determined in 291 paclitaxel and 151 docetaxel-treated patients, and were subsequently correlated with taxane clearance. RESULTS: In the patients treated with paclitaxel, no clinically relevant correlations between the 4β-OHC or 4β-OHC : cholesterol ratio and paclitaxel clearance were found. In the patients treated with docetaxel, 4β-OHC concentration was weakly correlated with docetaxel clearance in males (r = 0.35 P = 0.01, 95% CI 0.08, 0.58). Of the 10% patients with taxane outlier clearance values, 4β-OHC did correlate with docetaxel clearance in males (r = 0.76, P = 0.03, 95% CI 0.12, 0.95). CONCLUSION: There was no clinical correlation between paclitaxel clearance and the CYP3A4 activity markers 4β-OHC or the 4β-OHC : cholesterol ratio. A weak correlation was observed between 4β-OHC and docetaxel clearance, but only in males. This endogenous CYP3A4 marker has limited predictive value for taxane clearance in patients.
AIM: Taxanes are anti-cancer agents used to treat several types of solid tumours. They are metabolized by cytochrome P450 (CYP) 3A, displaying a large pharmacokinetic (PK) variability. In this study, we evaluated the endogenous CYP3A4 marker 4β-hydroxycholesterol (4β-OHC) as a potential individual taxane PK predictor. METHODS: Serum 4β-OHC and cholesterol concentrations were determined in 291 paclitaxel and 151 docetaxel-treated patients, and were subsequently correlated with taxane clearance. RESULTS: In the patients treated with paclitaxel, no clinically relevant correlations between the 4β-OHC or 4β-OHC : cholesterol ratio and paclitaxel clearance were found. In the patients treated with docetaxel, 4β-OHC concentration was weakly correlated with docetaxel clearance in males (r = 0.35 P = 0.01, 95% CI 0.08, 0.58). Of the 10% patients with taxane outlier clearance values, 4β-OHC did correlate with docetaxel clearance in males (r = 0.76, P = 0.03, 95% CI 0.12, 0.95). CONCLUSION: There was no clinical correlation between paclitaxel clearance and the CYP3A4 activity markers 4β-OHC or the 4β-OHC : cholesterol ratio. A weak correlation was observed between 4β-OHC and docetaxel clearance, but only in males. This endogenous CYP3A4 marker has limited predictive value for taxane clearance in patients.
Authors: A Henningsson; A Sparreboom; M Sandström; A Freijs; R Larsson; J Bergh; P Nygren; M O Karlsson Journal: Eur J Cancer Date: 2003-05 Impact factor: 9.162
Authors: Ulf Diczfalusy; Jun Miura; Hyung-Keun Roh; Rajaa A Mirghani; Jane Sayi; Hanna Larsson; Karl G Bodin; Annika Allqvist; Mary Jande; Jong-Wook Kim; Eleni Aklillu; Lars L Gustafsson; Leif Bertilsson Journal: Pharmacogenet Genomics Date: 2008-03 Impact factor: 2.089
Authors: Sharyn D Baker; Ming Zhao; Ping He; Michael A Carducci; Jaap Verweij; Alex Sparreboom Journal: Anal Biochem Date: 2004-01-15 Impact factor: 3.365
Authors: Stefan A J Buck; C Louwrens Braal; Maaike M Hofman; Esther Oomen-de Hoop; Peter de Bruijn; Inge M Ghobadi Moghaddam-Helmantel; Koen G A M Hussaarts; Mijntje B Vastbinder; Quirine C van Rossum-Schornagel; Ron H N van Schaik; Agnes Jager; Stijn L W Koolen; Ron H J Mathijssen Journal: Ther Adv Med Oncol Date: 2022-03-17 Impact factor: 8.168